Brief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
10/02/2026 15:17
Feb 10 (Reuters) - CASI Pharmaceuticals Inc CASI.O: CASI PHARMACEUTICALS REPORTS THE RECEIPT OF DRUG REGISTRATION CERTIFICATE FOR THIOTEPA IN CHINA CASI PHARMACEUTICALS INC: THE CERTIFICATE SHALL REMAIN VALID TILL FEBRUARY 1, 2031 Source text: [ID:n0001104659-26-012391] Further company coverage: CASI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary